European Union approves Wegovy for weight management

Novo Nordisk/Wegovy (semaglutide)

The EU authorized Wegovy (semaglutide 2.4 mg) for weight management in adults with obesity or overweight with weight-related conditions, alongside diet and exercise. In a trial of 1,961 people, the 2.4 mg dose reduced body weight by an average of 15% over 68 weeks versus 2% on placebo.

• 84% of Wegovy users lost at least 5% of body weight versus 31% on placebo; doses are ramped over 16 weeks.
• In a second trial of 611 adults, Wegovy users lost an average of 16% versus 6% on placebo.
• Most frequent side effects are headache, nausea, vomiting, diarrhea, and abdominal pain.
• Discontinuation due to gastrointestinal adverse effects occurred in less than 5% of users.